Tinnitus Week is supported by Lenire®
Learn more about Lenire® who are supporting Tinnitus Week and helping us to raise awareness of tinnitus
We’d like to thank Lenire® for supporting Tinnitus Week and for helping us to raise awareness of tinnitus.
Lenire tinnitus treatment device
Lenire by Neuromod Devices is the first and only FDA Approved bimodal neuromodulation tinnitus treatment device.
Lenire combines audio and tongue stimulation to retrain the brain to activate friendly audio pathways to shift focus away from tinnitus.
Lenire has been proven to be safe and effective in three large-scale clinical trials (TENT-A1, TENT-A2, TENT-A3) involving more than 500 tinnitus patients.
- TENT-A1: 80% of Lenire’s first clinical trial patients had a reduction in tinnitus severity that sustained for at least 12 months after treatment.
- TENT-A2: 91% of Lenire’s second clinical trial patients had a reduction in tinnitus severity that sustained for at least 12 months after treatment.
- TENT-A3 (Controlled Clinical Trial): 70.5% of those with moderate or worse tinnitus had clinically meaningful relief from tinnitus after 6-weeks of Lenire when 6-weeks of sound alone had no meaningful impact.
- Real World: A retrospective analysis of 220 American Patients showed that 91.5% of patients experienced clinically meaningful reduction in tinnitus after 12-weeks of treatment with Lenire.
Bimodal neuromodulation has been recognised by the American Tinnitus Association as an accepted standard of care for tinnitus.
You can see inspiring real world patient stories by visiting www.lenire.com/patient-stories